Joshua Grass, Escient Pharma CEO
November 28, 2022 11:01 AM ESTUpdated December 2, 02:27 AM
Financing

San Diego biotech lands $120M to launch a slate of tri­als in neu­rosen­so­ry dis­or­ders

Amber Tong

Days af­ter adding some fi­nance, deal­mak­ing and tech­ni­cal tal­ent to the top team, Escient Phar­ma has tak­en the wraps off a $120 mil­lion round to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times